Case 24

Published on 03/03/2015 by admin

Filed under Neurology

Last modified 03/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1022 times

Case 24

HISTORY AND PHYSICAL EXAMINATION

A 36-year-old white man awoke with binocular diplopia; later that day, he noted blurred vision and lid ptosis. The next morning, he had nausea and vomited twice, and then he had slurred speech and difficulty swallowing. He was admitted to the hospital where magnetic resonance imaging (MRI) of the brain and cerebral angiography were normal. By the third day, he had developed complete ophthalmoplegia, severe dysarthria and dysphagia, and upper extremity weakness. Respiratory failure followed; the patient had to be intubated and required assisted ventilation. The Tensilon test was equivocal.

On examination on day 4, the patient was alert and intubated, and followed commands well. He had bilateral complete ophthalmoplegia to all gaze directions with bilateral ptosis (Figure C24-1). Pupils were dilated and unreactive to light or attempted accommodation. Corneal reflexes were depressed. The patient had bilateral peripheral facial weakness. His tongue was extremely weak, with no fasciculations. His palate did not move volitionally or to gagging. Neck flexors and extensors were weak (Medical Research Council [MRC] 3/5), as were proximal pelvic and shoulder girdle muscles (4/5). However, distal muscles were normal. Deep tendon reflexes were depressed (1/4). Sensation was normal. Cerebellar function also was normal.

An electrodiagnostic (EDX) examination was requested.

Please now review the Nerve Conduction Studies and Needle EMG tables.

QUESTIONS

EDX FINDINGS AND INTERPRETATION OF DATA

The relevant EDX findings in this case are:

The EDX findings are consistent with a neuromuscular junction disorder of the presynaptic type, as supported by the borderline or low-amplitude baseline CMAPs, and the significant increment (>50%) of the CMAP amplitude after brief exercise and rapid repetitive stimulation of motor nerves. This case is consistent with botulism based on subacute progression of a descending muscle paralysis (ocular to bulbar to limbs), the muscarinic involvement (pupillary dilatation), and the EDX findings (presynaptic blockade). It is not consistent with Lambert-Eaton myasthenic syndrome because of the rapid evolution of symptoms, the prominent oculobulbar muscle weakness, and the relatively modest increment on rapid repetitive stimulation and after brief exercise (see electrodiagnosis).

DISCUSSION

Physiology and Pathophysiology

Botulinum toxin is produced by the anaerobic bacterium Clostridium botulinum. Eight immunologically distinct subtypes of the toxin have been identified (A, B, C1, C2, D, E, F, and G). Five serotypes are associated with human disease, with types A and B being the most common. Botulinum toxin type A is the most common in the United States, accounting for 60% of reported cases; it is the predominant type west of the Mississippi and is the most toxic of all subtypes. Type B serotype causes 30% of US cases and is the most common in Europe. It is the major type east of the Mississippi and tends to cause a milder illness.

Botulinum toxin is an extremely potent toxin with doses as small as 0.05 to 0.1 μg causing death in humans. The toxin has significant affinity to both muscarinic and nicotinic cholinergic nerve terminals resulting in autonomic failure and skeletal muscle paralysis. The toxin results in failure of ACH release from the presynaptic terminal and ultimately leads to destruction of the presynaptic terminal. Botulinum toxin first attaches irreversibly to the axonal terminal, and enters via endocytosis without interfering with the calcium channel (calcium entry is not blocked by botulinum toxin). The toxin then interferes with the calcium-dependent intracellular cascade that is responsible for ACH release, by cleaving proteins essential for docking and fusion of the presynaptic vesicles at the presynaptic active zones. Electron microscopy of nerve endings exposed to the toxin reveal a “log jam” of vesicles in the presynaptic terminals. It is now known that various serotypes bind to different presynaptic proteins: botulinum toxin A and E hydrolyze synaptosomal-associated protein-25 (SNAP-25), a protein of the presynaptic membrane; botulinum toxins B, D, F, and G specifically cleave synaptobrevin, a membrane protein of the neurotransmitter-containing vesicles; botulinum toxin C cleaves both SNAP-25 and syntaxin, a nerve plasmalemma protein (Figure C24-5

Buy Membership for Neurology Category to continue reading. Learn more here